Antibiotic resistance patterns in Pseudomonas aeruginosa: An 8-year surveillance study in a French hospital

International Journal of Antimicrobial Agents

Volumn 9, Issue 2, 1997, Pages 107-112

  Bert, Frédéric ^a   Lambert Zechovsky, Nicole ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Aminoglycosides; Antibiotic resistance; Beta lactams; Ciprofloxacin; O serotype; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAZIDIME; CEPHALOSPORINASE; CIPROFLOXACIN; FOSFOMYCIN; IMIPENEM; LIPOPOLYSACCHARIDE; PENICILLINASE; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FRANCE; HOSPITAL; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROTYPE;

EID: 0030801272     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00033-2     Document Type: Article

References (25)

1. Hancock REW. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1986;18:653-9.
2. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J. Med. Microbiol. 1995;43:300-9.
3. Thabaut A, Philippon A, Meyran M. β-Lactamases of Pseudomonas aeruginosa and susceptibility against β-lactam antibiotics. Chemoterapia 1985;4:36-42.
4. Vanhoof R, Godard C, Nulens E et al. Serotypes and extended spectrum beta-lactam resistance in aminoglycoside resistant Pseudomonas aeruginosa isolates from two Belgian general hospitals: a seven-year study. J. Hosp. Infect. 1993;24:129-38.
5. Verbist L. Incidence of multi-resistance in Gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scand. J. Infect. Dis. 1991;78:45-53.
6. Allemeersch D, Beumer J, Devleeschouwer M et al. Marked increase of Pseudomonas aeruginosa serotype O12 in Belgium since 1982. Eur. J. Clin. Microbiol. Infect. Dis. 1988;7:265-9.
7. Farmer III JJ, Weinstein RA, Zierdt CH, Brokopp CD. Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11. J. Clin. Microbiol. 1982;16:266-70.
8. Giammanco A, Stefano R, Aristas S, Sinatra A, Chiarini A, Infections caused by Pseudomonas aeruginosa: relative isolation of serogroup 12 from clinical specimens. Eur. J. Epidemiol. 1985;1:104-9.
9. Legakis NJ, Koukoubanis N, Malliara K, Micholitsianos D, Papavassiliou J. Importance of carbenicillin and gentamicin cross-resistant serotype O12 Pseudomonas aeruginosa in six Athens hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 1987;6:300-3.
10. Patzer J, Dzierzanowska D. The incidence of serotype O12 and multiresistance amongst Pseudomonas aeruginosa isolates. J. Antimicrob. Chemother. 1994;34:165-70.
11. Soussy, C.J., Cluzel, R., Courvalin, P. and the Comité de l'Antibiogramme de la Société Française de Microbiologie. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur. J. Clin. Microbiol. Infect. Dis. 1994;13:238-46.
12. Bert F, Briaud I, Branger C, Lambert-Zechovsky N. Comparaison de l'activité des β-lactamines sur Pseudomonas aeruginosa en fonction des phénotypes de résistance. Pathol. Biol. 1996;44:329-32.
13. Liu PV, Matsumoto H, Kusama H, Bergan T. Survey of heat stable, major somatic antigens of Pseudomonas aeruginosa. Int. J. Syst. Bacteriol. 1983;33:256-64.
14. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa : active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 1994;38:1742-52.
15. Livermore DM. Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and -susceptible strains of Pseudomonas aeruginosa. J. Med. Microbiol. 1984;18:261-70.
16. Leying HJ, Buscher KH, Cullmann W, Then RL. Lipopolysaccharide alterations responsible for combined quinolone and β-lactam resistance in Pseudomonas aeruginosa. Chemotherapy 1992;38:82-91.
17. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. 3. Antimicrob. Chemother. 1995;35:521-34.
18. Spencer RC. An 8 year Micro Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. J. Antimicrob. Chemother. 1996;37:295-301.
19. Buscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in Pseudumonas aeruginosa resulting from diminished expression of an outer membrane protein. J. Antimicrob. Chemother. 1987;31:703-8.
20. Shannon K, Phillips I. Mechanisms of resistance to aminoglycosides in clinical isolates. J. Antimicrob. Chemother. 1982;9:91-102.
21. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 1993;57:138-63.
22. Shearer BG, Legakis NJ. Pseudomonas aeruginosa: evidence for the involvement of lipopolysaccharide in determining outer membrane permeability to carbenicillin and gentamicin. J. Infect. Dis. 1985;152:351-5.
23. Pitt TL, Livermore DM, Miller G, Vatopoulos A, Legakis NJ. Resistance mechanisms of multiresistant serotype O12 Pseudomonas aeruginosa isolated in Europe. J. Antimicrob. Chemother. 1990;26:319-28.
24. Gilmore DS, Bruce SK, Jimenez EM, Schik DG, Morrow JW, Montgomerie JZ. Pseudomonas aeruginosa colonization in patients with spinal cord injuries. J. Clin. Microbiol. 1982;16:856-60.
25. Orsi GB, Mansi A, Tomao P, Ciarini F, Visca P. Lack of association between clinical and environmental isolates of Pseudomonas aeruginosa in hospital wards. J. Hosp. Infect. 1994;27:49-60.